Pubblicazioni

Autori:

Zivelonghi, Cecilia; Dinoto, Alessandro; Irani, Sarosh R; Mckeon, Andrew; Pilotto, Andrea; Padovani, Alessandro; Masciocchi, Stefano; Magni, Eugenio; Mancinelli, Chiara R; Capra, Ruggero; Maniscalco, Giorgia T; Volonghi, Irene; Easton, Ava; Alberti, Daniela; Zanusso, Gianluigi; Monaco, Salvatore; Salvagno, Gian Luca; Lippi, Giuseppe; Ferrari, Sergio; Mariotto, Sara

Titolo:

SARS-CoV-2 antibodies in inflammatory neurological conditions: a multicentre retrospective comparative study

Anno:

2023

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

A Stampa

Referee:

Sì

Nome rivista:

Immunologic Research

ISSN Rivista:

0257-277X

N° Volume:

71

Numero o Fascicolo:

5

Intervallo pagine:

717-724

Parole chiave:

Demyelinating disorders; Encephalitis; SARS-CoV-2; Viral trigger

Breve descrizione dei contenuti:

It is well established that neurological and non-neurological autoimmune disorders can be triggered by viral infections. It remains unclear whether SARS-CoV-2 infection induces similar conditions and whether they show a distinctive phenotype. We retrospectively identified patients with acute inflammatory CNS conditions referred to our laboratory for antibody testing during the pandemic (March 1 to August 31, 2020). We screened SARS-COV-2 IgA/IgG in all sera by ELISA and confirmed the positivity with additional assays. Clinical and paraclinical data of SARS-COV-2-IgG seropositive patients were compared to those of seronegative cases matched for clinical phenotype, geographical zone, and timeframe. SARS-CoV-2-IgG positivity was detected in 16/339 (4%) sera, with paired CSF positivity in 3/16. 5 of these patients had atypical demyelinating disorders and 11 autoimmune encephalitis syndromes. 9/16 patients had a previous history of SARS-CoV-2 infection and 6 of them were symptomatic. In comparison with 32 consecutive seronegative controls, SARS-CoV-2-IgG-positive patients were older, frequently presented with encephalopathy, had lower rates of CSF pleocytosis and other neurological autoantibodies, and were less likely to receive immunotherapy. When SARS-CoV-2 seropositive versus seronegative cases with demyelinating disorders were compared no differences were seen. Whereas seropositive encephalitis patients less commonly showed increased CSF cells and protein, our data suggest that an antecedent symptomatic or asymptomatic SARS-CoV-2 infection can be detected in patients with autoimmune neurological conditions. These cases are rare, usually do not have specific neuroglial antibodies.

Note:

Cecilia Zivelonghi and Alessandro Dinoto equally contributed to the study.

Pagina Web:

https://doi.org/10.1007/s12026-023-09384-2

Id prodotto:

133754

Handle IRIS:

11562/1093770

ultima modifica:

6 dicembre 2023

Citazione bibliografica:

Zivelonghi, Cecilia; Dinoto, Alessandro; Irani, Sarosh R; Mckeon, Andrew; Pilotto, Andrea; Padovani, Alessandro; Masciocchi, Stefano; Magni, Eugenio; Mancinelli, Chiara R; Capra, Ruggero; Maniscalco, Giorgia T; Volonghi, Irene; Easton, Ava; Alberti, Daniela; Zanusso, Gianluigi; Monaco, Salvatore; Salvagno, Gian Luca; Lippi, Giuseppe; Ferrari, Sergio; Mariotto, Sara, SARS-CoV-2 antibodies in inflammatory neurological conditions: a multicentre retrospective comparative study «Immunologic Research» , vol. 71 , n. 5 , 2023 , pp. 717-724

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo